Precision oncology: A strategy we were not ready to deploy

Seminars in Oncology

Volumn 43, Issue 1, 2016, Pages 9-12

  Fojo, Tito ^a  

^a Howard Hughes Medical Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DATA ANALYSIS; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; ONCOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); EVIDENCE BASED NURSING; GENETICS; NEOPLASMS; PERSONALIZED MEDICINE; PHARMACOGENETICS;

EVIDENCE-BASED NURSING; HUMANS; NEOPLASMS; PHARMACOGENETICS; PRECISION MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84960414362     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2016.01.005     Document Type: Editorial

References (18)

1. B.J. Druker, M. Talpaz, D.J. Resta, and et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037
2. https://en.wikiquote.org/wiki/Simplicity. Attributed to Albert Einstein. Possibly paraphrased from remarks in "On the Method of Theoretical Physics", Herbert Spencer Lecture, Oxford (10 June 1933), Philosophy of Science, Vol. 1, No. 2 (April 1934), pp. 163-169, p. 165.
3. B.J. Druker, C.L. Sawyers, H. Kantarjian, and et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 2001 1038 1042
4. G. Iyer, A.J. Hanrahan, M.I. Milowsky, and et al. Genome sequencing identifies a basis for everolimus sensitivity Science 338 2012 221
5. The origin of this phrase can likely be attributed to Frank Kotsonis or Roger Brinner. https://sites.google.com/site/skepticalmedicine//the-plural-of-anecdote-is-not-data ], [last accessed 1/19/2106].
6. V. Prasad, and A. Vandross Characteristics of exceptional or super responders to cancer drugs Mayo Clin Proc 90 2015 1639 1649
7. D.D. Von Hoff, J.J. Stephenson Jr., P. Rosen, and et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers J Clin Oncol 28 2010 4877 4883
8. J.H. Doroshow Selecting systemic cancer therapy one patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors? J Clin Oncol 28 2010 4869 4871
9. D.M. Hyman, I. Puzanov, V. Subbiah, and et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations N Engl J Med 373 2015 726 736
10. C. Le Tourneau, J.P. Delord, A. Gonçalves, and et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial Lancet Oncol 16 2015 1324 1334
11. C. Robert, B. Karaszewska, J. Schachter, and et al. Improved overall survival in melanoma with combined dabrafenib and trametinib N Engl J Med 372 2015 30 39
12. J. Larkin, P.A. Ascierto, B. Dréno, and et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma N Engl J Med 371 2014 1867 1876
13. http://www.wnyc.org/story/why-war-cancer-hasnt-been-won/ [last accessed 1/19/2106].
14. A. Ribas, F.S. Hodi, M. Callahan, C. Konto, and J. Wolchok Hepatotoxicity with combination of vemurafenib and ipilimumab N Engl J Med 368 2013 1365 1366
15. http://www.npr.org/sections/health-shots/2015/03/26/394327128/why-doctors-are-trying-a-skin-cancer-drug-to-treat-a-brain-tumor [last accessed 1/19/2106].
16. http://time.com/3750523/the-cancer-gap/ [last accessed 1/19/2106].
17. J.C. Chen, M.J. Alvarez, F. Talos, and et al. Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks Cell 159 2014 402 414
18. Prasad V, Fojo T, Brada M. The origins and optimism of precision oncology and radiotherapy and what it will take to live up to the promise. Lancet Oncol. In press.